International Nonproprietary Name "temelimab" Assigned to GNbAC1 Temelimab’s robust safety and tolerability profile confirmed High-dose regimen fully validated by pharmacokinetic data Enables higher dos ...
NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors Dose-escalation part of study met primary objective Study shows NP137 to hav ...
After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were reduced by 23% in the 400mg BID group (p<0.01) In patients with higher baseline GGT, reduction in GGT levels was even greater wi ...
Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide development rights GeN ...
. Positive effects observed on key neuroprotection endpoints related to MS disease progression . Neuroprotective effects also seen in non-active MS patient . Confirmation of safety and tolerability Geneva, Switz ...
. GKT831 achieves marked anti-fibrotic effects in clinically relevant model of advanced cholestatic disease . Interim results of the Phase 2 Clinical Trial with GKT831 in Primary Biliary Cholangitis expected in early ...
